XTalks

SEPTEMBER 5, 2023

Xtalks spoke with Maria Reyes Boceta-Muñoz, Clinical Operations Head of Development R&D at GlaxoSmithKline in Spain, Portugal & Israel, to understand the current vaccine development climate and where the sector is headed. However, guidelines do not provide matters specific to each vaccine type.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

The Pharma Data

JANUARY 3, 2021

We are very honored to have someone of Dr. Zeldis’ caliber lead our scientific research and clinical development teams. At NexImmune, he will oversee all aspects of research and development. The backbone of NexImmune’s approach is its proprietary Artificial Immune Modulation (AIM TM ) nanoparticle technology platform.

Immune Response 40

Immune Response Clinical Trials Clinical Trials Development 40

XTalks

MARCH 13, 2023

Another thing Dr. Xu recommended is to monitor the immune response to gene therapy products. Immune assays were recommended to measure both cellular and human immune responses to the viral vector and the transgene, as applicable.

Gene Therapy 52

Gene Therapy Clinical Trials Clinical Trials Gene 52

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc., announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

The Pharma Data

NOVEMBER 1, 2020

Clinical Data Expected by End of Year. Tiziana Life Sciences plc. (“Tiziana” or the “Company”). C linical study will start dosing patients on November 3 rd , 202 0 with clinical data expected to be available before the end of 2020. About Tiziana Life Sciences.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Life Science 52

XTalks

NOVEMBER 15, 2023

XTALKS WEBINAR: Vaccine Clinical Development: Key Ingredients to Improve Efficiency Live and On-Demand: Monday, November 20, 2023, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn ways to improve the efficiency of vaccine development.

FDA Approval 59

FDA Approval Vaccination Vaccine In-Vitro 59

The Pharma Data

DECEMBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. We are encouraged by the data shown in these two studies of GPS in combination with checkpoint inhibitors and look forward to additional data from these studies,” stated Dragan Cicic, MD, Senior Vice President, Clinical Development of SELLAS. “We

Life Science 52

Life Science Immune Response Trials Clinical Trials 52

Delveinsight

AUGUST 4, 2021

Similarly, genetics, immune response, and environmental factors also influence the occurrence of Neurological Conditions. Similarly, other companies in the domain such as Eisai/ BioArctic AB, Hoffmann-La Roche/Chugai Pharmaceuticals, Anavex Life Sciences Corp., Parkinson’s Disease.

Marketing 98

Marketing Genetics Development Clinical Development 98

The Pharma Data

JANUARY 19, 2021

The year is starting off with a number of biopharma and life sciences initial public offerings (IPOs). The compound was developed in the laboratory of Richard Childs, chief of the Laboratory of Transplantation Immunotherapy with the National Heart, Lung, and Blood Institute (NHLBI). TCR2 Therapeutics – The Cambridge, Mass.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

XTalks

JUNE 9, 2022

Its invention has allowed Regeneron to become a leading antibody therapeutics company, with twelve clinical stage antibodies generated through our VelocImmune platform currently in clinical development.”. These antibodies bind strongly to their target and provide a robust immune response.

Trials 52

Trials Antibody Genetics Gene 52

XTalks

AUGUST 18, 2021

Of important note is the aberrant immune response that occurs in patients with COVID-19, including the intensive release of cytokines (cytokine storm), which can make a patient infected with SARS-CoV2 more susceptible to contracting a bacterial respiratory infection. Addressing AMR has to become a priority again.”.

Development 105

Development Bacteria Drugs Vaccination 105

Drug Discovery World

NOVEMBER 13, 2023

Enkelejda Miho, PhD, Professor, University of Applied Sciences and Arts Northwestern Switzerland, and Managing Director, aiNET, on: ‘The singular immune response to dengue and machine learning identification of antibodies in high-throughput sequences’. It is called, ‘An unexpected future for immune oncology therapies?’

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research 52

Research In-Vitro In-Vivo Development 52

XTalks

SEPTEMBER 14, 2020

It was recently reported that the addition of an adjuvant to their vaccine led to enhanced immune responses that exceeded responses in convalescent serum from symptomatic COVID-19 patients. Novavax has also tested its recombinant SARS-CoV-2 nanoparticle adjuvanted vaccine in a Phase I/II trial.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92